MISSISSAUGA, ON, June 29 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND - News) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for CIP-TRAMADOL ER, an extended-release capsule formulation of the pain medication tramadol. Cipher is seeking approval to market CIP-TRAMADOL ER for the treatment of moderate to moderately severe pain.
